U.S. markets closed
  • S&P Futures

    4,161.25
    -22.25 (-0.53%)
     
  • Dow Futures

    34,610.00
    -58.00 (-0.17%)
     
  • Nasdaq Futures

    13,208.50
    -148.25 (-1.11%)
     
  • Russell 2000 Futures

    2,187.10
    -22.50 (-1.02%)
     
  • Crude Oil

    64.54
    -0.38 (-0.59%)
     
  • Gold

    1,835.50
    -2.10 (-0.11%)
     
  • Silver

    27.37
    -0.12 (-0.44%)
     
  • EUR/USD

    1.2137
    +0.0003 (+0.02%)
     
  • 10-Yr Bond

    1.6020
    +0.0250 (+1.59%)
     
  • Vix

    19.66
    +2.97 (+17.80%)
     
  • GBP/USD

    1.4116
    -0.0005 (-0.04%)
     
  • USD/JPY

    108.9360
    +0.0950 (+0.09%)
     
  • BTC-USD

    55,679.45
    -2,999.18 (-5.11%)
     
  • CMC Crypto 200

    1,464.36
    -96.93 (-6.21%)
     
  • FTSE 100

    7,123.68
    -6.03 (-0.08%)
     
  • Nikkei 225

    28,862.63
    -655.71 (-2.22%)
     

Biotechnology trade group taps former Biogen CEO as its coronavirus czar

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
By Rebecca Spalding
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

By Rebecca Spalding

Feb 28 (Reuters) - The Biotechnology Innovation Organization (BIO), the biotechnology industry's largest trade association, told Reuters on Friday that former Biogen Inc CEO George Scangos would coordinate its response to the global coronavirus outbreak.

Scangos, currently the chief executive of San Francisco-based start-up Vir Biotechnology, which is working on a coronavirus treatment, will lead BIO's efforts to research therapeutics and diagnostics to stave off the spread of the virus.

"The role is still evolving but it is clear someone needs to pick up the reins. It is only natural for us here at Vir to take on a leadership role," Scangos said in an interview.

A BIO spokesman said about 40 of its members have reached out to the organization to offer their expertise, while about 20 are researching therapeutics, vaccines or diagnostics that target the virus. BIO has spent the last few weeks tracking the programs already under way and helping firms coordinate with one another and government authorities, the spokesman said.

The initiative may have the most value for small biotechnology firms, which unlike their bigger peers are perennially low on cash. Some have never developed a therapy all the way through regulatory approval and have little experience working with agencies such as the U.S. Department of Health and Human Services or the Department of Defense let alone international authorities.

Vir is one of the several companies working on a coronavirus treatment. On Tuesday, Vir announced it had discovered several antibodies that bind to the coronavirus, dubbed COVID-19, after studying patients who survived SARS, a related virus.

The company said it would continue its research in partnership with Chinese drug company WuXi Biologics. Moderna Inc and Gilead Sciences Inc have also said they are researching treatments to combat the virus. Experts have said that a vaccine would likely take at least between 12 and 18 months to develop.

The latest World Health Organization figures indicate over 82,000 people have been infected, with over 2,700 deaths in China and 57 deaths in 46 other countries. (Reporting by Rebecca Spalding in New York Editing by Leslie Adler)